Amylyx Pharmaceuticals Common Stock Public Offering Plan

On March 13, 2023, a preliminary prospectus supplement was filed with the Securities and Exchange Commission (SEC). This supplement provides important information about an upcoming offering of securities, giving potential investors insight into the terms and conditions of the investment opportunity.

Investors should carefully review the prospectus supplement to understand the risks, benefits, and details of the securities being offered. It is essential to conduct thorough due diligence and consult with a financial advisor before making any investment decisions.

The prospectus supplement will outline key information such as the offering price, number of securities being offered, and any special terms or conditions attached to the investment. This information is crucial for investors to assess whether the opportunity aligns with their investment goals and risk tolerance.

By reviewing the prospectus supplement, investors can make informed decisions about whether to participate in the offering. It is important to consider all available information and seek guidance from professionals to ensure that investments are in line with one’s financial objectives.

Remember, investing always carries some level of risk, so it is important to approach any investment opportunity with caution and diligence. By thoroughly reviewing the prospectus supplement and seeking advice when needed, investors can make well-informed decisions that align with their financial goals.